<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Chemother Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Chemother. Pharmacol</journal-id><journal-title-group><journal-title>Cancer Chemotherapy and Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0344-5704</issn><issn pub-type="epub">1432-0843</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29159475</article-id><article-id pub-id-type="pmc">5778164</article-id><article-id pub-id-type="publisher-id">3457</article-id><article-id pub-id-type="doi">10.1007/s00280-017-3457-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Markus</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Chow</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Zhiying</given-names></name><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hanes</surname><given-names>Vladimir</given-names></name><address><phone>+1 805 447 5012</phone><email>vhanes@amgen.com</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0657 5612</institution-id><institution-id institution-id-type="GRID">grid.417886.4</institution-id><institution>Biosimilars Development, Amgen Inc., </institution></institution-wrap>One Amgen Center Drive, Thousand Oaks, CA 91320 USA </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>81</volume><issue>2</issue><fpage>419</fpage><lpage>419</lpage><permissions><copyright-statement>© The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.</license-p></license></permissions><related-article related-article-type="corrected-article" id="d29e85" ext-link-type="doi" xlink:href="10.1007/s00280-017-3416-4"></related-article><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer-Verlag GmbH Germany, part of Springer Nature 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title><offsets xml_i="3656" xml_f="3741" txt_i="7" txt_f="92">Correction to: Cancer Chemother Pharmacol (2017) 80:755–763 10.1007/s00280-017-3416-4</offsets></title><p><offsets xml_i="3752" xml_f="4401" txt_i="93" txt_f="742">The article [A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men], written by [Richard Markus, Vincent Chow, Zhiying Pan and Vladimir Hanes], was originally published Online First without open access. After publication in volume [80], issue [4], page [755–763] the author decided to opt for Open Choice and to make the article an open access publication. Therefore, the copyright of the article has been changed to © The Author(s) [2017] and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (</offsets><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/"><offsets xml_i="4488" xml_f="4531" txt_i="742" txt_f="785">http://creativecommons.org/licenses/by/4.0/</offsets></ext-link><offsets xml_i="4542" xml_f="4843" txt_i="785" txt_f="1086">), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The original article was corrected.</offsets></p></sec></body><back><fn-group><fn><p>The original article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00280-017-3416-4">https://doi.org/10.1007/s00280-017-3416-4</ext-link>.</p></fn></fn-group></back></article>